Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
MANEthis companyVeradermics, Incorporated	$140.60	-15.86×	-10.94×	0×	-18.61×	-99.5%	0.0%	0.0%	0.0%	57.8%	-50.4%	-5.4%	-0×	0.31×	0×	16.66×	0.0%	2	289.37	2	C
ABEOAbeona Therapeutics Inc.	$2.48	3.93×	1.75×	47.95×	2.87×	-76.4%	73.7%	-1536.9%	1223.1%	44.7%	-44.0%	-30.2%	0.16×	-0.68×	-23.92×	6.93×	0.0%	2	-3.55	2	C
DRMADermata Therapeutics, Inc.	$0.76	-0.28×	0.35×	0×	0.69×	916.2%	0.0%	0.0%	0.0%	-121.5%	-124.9%	-361.0%	0×	0.97×	0×	4.79×	0.0%	1	-23.83	2	C+
LSTALisata Therapeutics, Inc.	$1.09	-0.97×	1.09×	95.05×	-0.01×	89.2%	14.1%	-10711.2%	-9756.5%	-111.7%	-117.3%	-98.9%	0×	0.92×	0×	5.76×	0.0%	1	-74.76	2	C
OVIDOvid Therapeutics Inc.	$2.99	-6.79×	0.92×	16.57×	-7.03×	-129.6%	95.9%	-585.2%	-240.1%	-13.3%	-29.5%	-31.9%	0.1×	-0.02×	0×	10.91×	0.0%	1	10.63	2	C+
PLYXPolaryx Therapeutics, Inc. Common Stock	$1.86	-184.21×	362.98×	0×	-183.85×	-94.3%	0.0%	0.0%	0.0%	-196.8%	-162.4%	-0.2%	0×	0.57×	0×	8.55×	0.0%	3	46.88	1	D+
Peer median	—	-0.97×	1.09×	16.57×	-0.01×	-76.4%	14.1%	-585.2%	0.0%	-111.7%	-117.3%	-31.9%	0×	0.57×	0×	6.93×	0.0%	1	-3.55	2	—